Matches in Nanopublications for { ?s ?p "[This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP474133.RACkXp7eTYnUhANBpifUD2zjfuxsIHefJuxORBoGwdJ0Y130_assertion description "[This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474133.RACkXp7eTYnUhANBpifUD2zjfuxsIHefJuxORBoGwdJ0Y130_provenance.
- NP547050.RAeq6yGjh3jVxiSMeILCBg32_uRS6eGD4PsBcUJvw4fwo130_assertion description "[This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP547050.RAeq6yGjh3jVxiSMeILCBg32_uRS6eGD4PsBcUJvw4fwo130_provenance.
- NP556231.RAQ8mZ7GnRHnq8cr7PWnbpGkFO6dYxG-4afuiFV1viqWM130_assertion description "[This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP556231.RAQ8mZ7GnRHnq8cr7PWnbpGkFO6dYxG-4afuiFV1viqWM130_provenance.
- NP896090.RAboQKIlMKN77zNnF-ffQugycJOR7gHUZ53QfhgSJHyRc130_assertion description "[This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP896090.RAboQKIlMKN77zNnF-ffQugycJOR7gHUZ53QfhgSJHyRc130_provenance.
- NP896088.RALWf-BdYm39dBwE5u6GmOTicQKh3nzjrPItPCGx8rgns130_assertion description "[This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP896088.RALWf-BdYm39dBwE5u6GmOTicQKh3nzjrPItPCGx8rgns130_provenance.